- Home
- SRAD vs INDV Comparison
SRAD vs INDV Comparison
Compare SRAD & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRAD | INDV |
|---|---|---|
| Founded | 2001 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.7B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SRAD | INDV |
|---|---|---|
| Price | $13.24 | $35.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $24.31 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 04-28-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 1.67 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $24.03 | N/A |
| Revenue Next Year | $14.81 | N/A |
| P/E Ratio | $49.48 | ★ $21.57 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $11.55 | $22.56 |
| 52 Week High | $29.41 | $42.81 |
Technical Indicators
Market Signals| Indicator | SRAD | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 52.03 |
| Support Level | $12.55 | $35.49 |
| Resistance Level | $13.75 | $36.62 |
| Average True Range (ATR) | 0.62 | 0.89 |
| MACD | 0.08 | 0.32 |
| Stochastic Oscillator | 61.80 | 74.68 |
Price Performance
Historical ComparisonAbout SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).